ES2061024T3 - Uso terapeutico de antagonistas de receptores de 5-ht3. - Google Patents

Uso terapeutico de antagonistas de receptores de 5-ht3.

Info

Publication number
ES2061024T3
ES2061024T3 ES90905482T ES90905482T ES2061024T3 ES 2061024 T3 ES2061024 T3 ES 2061024T3 ES 90905482 T ES90905482 T ES 90905482T ES 90905482 T ES90905482 T ES 90905482T ES 2061024 T3 ES2061024 T3 ES 2061024T3
Authority
ES
Spain
Prior art keywords
receptor antagonists
therapeutic use
disorders
agoraphobia
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90905482T
Other languages
English (en)
Inventor
Alberto Azcona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898909147A external-priority patent/GB8909147D0/en
Priority claimed from GB898916602A external-priority patent/GB8916602D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of ES2061024T3 publication Critical patent/ES2061024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LOS ANTAGONISTAS RECEPTORES 5-HT3 SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES DE PANICO Y/O AGORAFOBIA O ENFERMEDADES COMPULSIVAS OBSESIVAS.
ES90905482T 1989-04-21 1990-04-06 Uso terapeutico de antagonistas de receptores de 5-ht3. Expired - Lifetime ES2061024T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898909147A GB8909147D0 (en) 1989-04-21 1989-04-21 Improvements in or relating to organic compounds
GB898916602A GB8916602D0 (en) 1989-07-20 1989-07-20 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
ES2061024T3 true ES2061024T3 (es) 1994-12-01

Family

ID=26295258

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90905482T Expired - Lifetime ES2061024T3 (es) 1989-04-21 1990-04-06 Uso terapeutico de antagonistas de receptores de 5-ht3.

Country Status (10)

Country Link
EP (1) EP0422154B1 (es)
JP (1) JPH0669963B2 (es)
KR (1) KR920700034A (es)
AT (1) ATE97803T1 (es)
AU (1) AU631632B2 (es)
CA (1) CA2031214A1 (es)
DE (1) DE69004924T2 (es)
DK (1) DK0422154T3 (es)
ES (1) ES2061024T3 (es)
WO (1) WO1990012569A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
US5763459A (en) * 1992-05-23 1998-06-09 Smithkline Beecham P.L.C. Medicaments for the treatment of anxiety
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
JP5387648B2 (ja) 2011-10-14 2014-01-15 株式会社デンソー 指針表示装置

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1365296A (en) * 1970-10-30 1974-08-29 Unilever Ltd Dentifrice compositions
EP0099194A3 (en) * 1982-07-03 1984-04-11 Beecham Group Plc Novel benzamides
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
EP0191562B1 (en) 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolone derivatives
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
GB8518743D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518741D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8518745D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
EP0212398A2 (de) 1985-08-21 1987-03-04 Siemens Aktiengesellschaft Verfahren zur Erkennung von Mehrfrequenzcodesignalen mit überlagerten Störsignalen
IL80707A (en) 1985-12-23 1991-03-10 Hughes Aircraft Co Gaseous discharge device simmering circuit
GB8701494D0 (en) 1987-01-23 1987-02-25 Glaxo Group Ltd Chemical compounds
DE3771376D1 (de) 1986-03-17 1991-08-22 Glaxo Group Ltd Indol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB8617994D0 (en) 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds
EP0254584B1 (en) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
HU895334D0 (en) 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
GB8623819D0 (en) 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
WO1988003801A1 (en) 1986-11-21 1988-06-02 Glaxo Group Limited Medicaments for treatment or prevention of withdrawal syndrome
GR871809B (en) 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
DE3780276T2 (de) * 1986-12-16 1993-02-25 Robins Co Inc A H Angstloesende n-(1-azabicyclo(2.2.2)oct-3-yl)benzamide und -thiobenzamide.
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
DE3876006T2 (de) 1987-04-14 1993-03-25 Glaxo Group Ltd Keton-derivate.
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
GB8720693D0 (en) 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
PH25493A (en) 1987-09-03 1991-07-24 Glaxo Group Ltd 2,3,4,5-tetrahydro-2-£(imidazol-(or-5)-yl)methyl-ih-pyrido£4,3-b|indol-1-ones , derivatives having 5-ht antagonist activity 3
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
JPH01258673A (ja) 1987-10-22 1989-10-16 Glaxo Group Ltd ケトン誘導体
DE3740984A1 (de) * 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
GB8802127D0 (en) 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
EP0329932B1 (en) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
EP0329904A1 (en) * 1988-02-23 1989-08-30 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
US5116984A (en) 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
US4863921A (en) 1988-04-27 1989-09-05 Rorer Pharmaceutical Corporation Dibenzofurancarboxamides and their pharmaceutical compositions and methods
US4985422A (en) 1988-04-27 1991-01-15 Glaxo Group Limited Lactam derivatives
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP0422154B1 (en) 1993-12-01
EP0422154A1 (en) 1991-04-17
CA2031214A1 (en) 1990-10-22
DE69004924D1 (de) 1994-01-13
AU631632B2 (en) 1992-12-03
AU5415890A (en) 1990-11-16
JPH03505881A (ja) 1991-12-19
DK0422154T3 (da) 1994-03-07
DE69004924T2 (de) 1994-05-19
JPH0669963B2 (ja) 1994-09-07
KR920700034A (ko) 1992-02-19
ATE97803T1 (de) 1993-12-15
WO1990012569A1 (en) 1990-11-01

Similar Documents

Publication Publication Date Title
BR9007938A (pt) Metodo e aparelho o tratamento de glaucoma
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
IT1232889B (it) Composizioni e procedimento per il trattamento ammorbidente di tessuti
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE69834693D1 (de) Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
BR9000990A (pt) Composicao aquosa condicionadora de tecidos e processo para o tratamento de tecidos
ATE234180T1 (de) Vorrichtung zum herstellen und gleichzeitigem verteilen von zementmischungen oder dergleichen
DE69630321D1 (de) Vorrichtung zur örtlichen wärmebehandlung von gewebe
DE69712578T2 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
ES2061024T3 (es) Uso terapeutico de antagonistas de receptores de 5-ht3.
BR8901135A (pt) Composicao para condicionamento de tecido e processo para tratar tecidos
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
BR9708109A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de distúrbios depressivos e distúrbios bipolares
ATA136490A (de) Behandlungsliege zur klangtherapie
DE69709287D1 (de) Mustererzeugungsverfahren und Oberflächenbehandlungsmittel
DE69025246D1 (de) Weichmachen von Gewebe
DE69412178T2 (de) Apparat zur Behandlung von Lagen
ATE197703T1 (de) Gerät zum entsalzen und aufbereiten von wasser
ATA29989A (de) Einrichtung zum feinblasigen belueften von abwasser
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
DE69001060D1 (de) Vorrichtung zur unterhaltung und reparatur von brueckendecken ohne verkehrsunterbrechung.
IT8920839A0 (it) Procedimento e dispositivo per la realizzazione di pannelli.
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 422154

Country of ref document: ES